10 Best Immunology Stocks To Buy Now

3. Incyte Corporation (NASDAQ:INCY) 

Number of Hedge Fund Holders: 49

Incyte Corporation (NASDAQ:INCY) is a global biopharmaceutical company focused on immunology, with expertise in dermatology, oncology, and autoimmune diseases. In dermatology, the company is developing treatments for immune-mediated conditions like atopic dermatitis and vitiligo, notably with ruxolitinib cream (Opzelura), which has shown promising results.

In oncology, Incyte Corporation (NASDAQ:INCY) is advancing cancer immunotherapy through targeted therapy discovery, functional genomics, and combination therapies targeting immune checkpoints like PD-1 and LAG-3, making it one of the best immunology stocks to watch.

In addition, Incyte Corporation (NASDAQ:INCY) is a leader in therapies for myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD), with ongoing clinical trials evaluating novel treatments like axatilimab and ruxolitinib-based combinations. Recently, the corporation realigned its R&D priorities by focusing on dermatology and inflammation assets, particularly those acquired from Escient Pharmaceuticals, and discontinuing early-stage immunotherapies. The company continues its diverse clinical programs and supports independent research through its Investigator-Initiated Research program.

Incyte Corporation (NASDAQ:INCY)’s Q4 2024 financial report showed strong growth, with total revenue reaching $1.2 billion, a 16% increase year-over-year. For the full year, revenue rose 15% to $4.2 billion. Jakafi (ruxolitinib) generated $773 million in Q4, up 11%, and $2.8 billion for the full year, an 8% increase. Opzelura (ruxolitinib) cream saw impressive growth, with Q4 revenues reaching $162 million, up 48%, and $508 million for the full year, a 50% increase. For 2025, Incyte Corporation (NASDAQ:INCY) projects Jakafi revenues to range between $2.93 – $2.98 billion and Opzelura between $630 – $670 million. The company also anticipates four new product launches, including Niktimvo for chronic graft-versus-host disease. The corporation completed a $2 billion share repurchase and maintains a strong balance sheet with $2.2 billion in cash and no debt.